Johnson & Johnson announced that TREMFYA® (guselkumab) demonstrated rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement in scalp itch, as well as patient-reported health-related quality of life outcomes, including post-inflammatory pigmentation at 16 weeks. Topline data from Cohort B in the Phase 3b VISIBLE study were presented at the Maui Derm Hawaii 2024 conference. VISIBLE is the first prospective, large-scale, randomized-controlled trial dedicated to people of color across all skin tones with moderate to severe plaque PsO and scalp PsO to objectively measure clearance and other treatment outcomes with TREMFYA.

The VISIBLE clinical program will produce an expansive longitudinal collection of more than 20,000 clinical images across all skin tones to support patients and providers with disease recognition and education. Cohort B of the study enrolled 108 people of color with scalp predominant moderate-to-severe PsO, a clinically proven difficult-to-treat area. TREMFYA demonstrated significant and rapid scalp PsO clearance and improvement in scalp itch as well as patient-reported health-related quality of life (HRQoL) outcomes.

Cohort A of the VISIBLE study, announced in October 2023, focused on patients of color with skin predominant PsO and provided additional data on the safety and effectiveness of TREMFYA across all skin tones. Coupled with the latest Cohort B findings, the collective data reinforces that the unique study design of VISIBLE is a successful model to enroll, retain and support people of color who have historically been undertreated and underrepresented in clinical trials, and an inclusive research process may create lasting impact on furthering medical education and patient education.